Clinical trial readiness biomarkers for gene dosage-dependent disorders

基因剂量依赖性疾病的临床试验准备生物标志物

基本信息

  • 批准号:
    10675478
  • 负责人:
  • 金额:
    $ 20.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-22 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

DNA-based therapy has made tremendous advances recently, as evident by the increase in emerging potential therapies such as gene replacement and antisense oligonucleotides to alter splicing or downregulate an extra allele. These therapies hold the promise to treat many IDDs; however, major challenges must be addressed to achieve successful clinical trials. Safety of such therapies is of the utmost importance since many of the genes are dosage sensitive. It is therefore critical to identify outcome measures sensitive to target engagement and able to detect overtreatment and unintended conversion of gain-of-function phenotypes into a loss-of-function phenotypes, and vice versa. Here, we focus on MECP2- (Rett vs. MECP2 Duplication), RAI1- (Smith-Magenis vs. Potocki-Lupski syndrome) and SHANK3- (Phelan-McDermid vs. SHANK3 Duplication) associated disorders as test cases of IDDs that are caused by alterations of these dosage-dependent genes. We propose to identify molecular and neurocircuitry mediators/effectors of dosage alterations of these genes, both peripherally and centrally, to develop composite biomarkers that are responsive to gene dosage in each individual at their particular disease stage. Toward this goal, we capitalize on the established patient cohorts at Baylor College of Medicine, which has an extensive history in studying these disorders and their genetics. In Aim 1, we will establish patient-specific molecular signatures of human induced neurons (iNs), derived from both fibroblasts and inducible pluripotent stem cells, and blood, using metabolomics and transcriptomics. In Aim 2, we will establish patient-specific autonomic and sensory neurocircuitry signatures of the momentary disease stage and severity using novel pre-pulse inhibition paradigm, pupillometry, and evoked potentials. These signatures will be obtained twice from the same subject, 8-12 months apart, to assess stability. We will then integrate these dense multimodal datasets from each subject to generate a composite biomarker that accurately represents personalized response to the gene dosage level at that particular time. In contrast to conventional population studies – and in the spirit of precision medicine – this analysis framework relies on complete and diverse datasets from each participant because safety at the individual level is paramount to avoid causing unintended phenotypes. This project is possible because of the ability to access the innovative services from all the cores. The strategies we develop will provide a template to advance the use of DNA-based therapy for treatment of many monogenic disorders and could help inform many disorders that are gene dosage- dependent. The patient-specific cell lines, molecular, and circuit data will be available for the scientific community in perpetuity, will complement natural history studies, and will inform future clinical trials. Lastly, the new methodologies for examining neurocircuitry and the integrative data analysis approaches at multiple levels will potentially provide transformative tools and analytical algorithms for assessment, safe dosing, and accelerated clinical trials for multiple gene dosage-dependent IDDs.
最近,基于DNA的治疗取得了巨大的进步,这一点可以从新出现的潜力的增加中得到证明。 治疗如基因置换和反义寡核苷酸以改变剪接或下调额外的 等位基因这些疗法有望治疗许多IDD;然而,必须解决主要挑战, 实现成功的临床试验。这种疗法的安全性是最重要的,因为许多基因 对剂量敏感。因此,必须确定对目标参与敏感的成果衡量标准, 能够检测过度治疗和功能获得表型向功能丧失表型的非预期转化 表型,反之亦然。在这里,我们关注MECP 2-(Rett vs. MECP 2 Duplication)、RAI 1-(Smith-Magenis vs. Potocki-Lupski综合征)和SHANK 3-(麦-麦二氏与SHANK 3复制)相关疾病 作为由这些剂量依赖性基因的改变引起的IDDs的测试案例。我们建议确定 分子和神经回路介质/这些基因的剂量改变的效应,无论是外周和 集中地,开发复合生物标志物,这些生物标志物在每个个体的 特殊疾病阶段。为了实现这一目标,我们利用贝勒大学的既定患者队列, 医学 在研究这些疾病及其遗传学方面有着广泛的历史。在目标1中,我们 建立人诱导神经元(iN)的患者特异性分子特征, 以及诱导性多能干细胞和血液。在目标2中,我们将 建立瞬时疾病阶段的患者特异性自主神经和感觉神经回路特征 和严重性使用新的前脉冲抑制范例,瞳孔测量,和诱发电位。这些签名 将从同一受试者中获得两次,间隔8-12个月,以评估稳定性。我们将整合 这些来自每个受试者的密集的多模态数据集,以生成复合生物标志物, 代表在特定时间对基因剂量水平的个性化反应。相比于常规 人口研究-并在精准医学的精神-这一分析框架依赖于完整的, 来自每个参与者的不同数据集,因为个人层面的安全至关重要,以避免导致 非预期表型。该项目之所以成为可能,是因为有能力获得创新服务, 所有的核心。我们开发的策略将提供一个模板,以促进基于DNA的治疗的使用, 治疗许多单基因疾病,并可以帮助告知许多疾病是基因剂量- 依赖。患者特异性细胞系、分子和电路数据将可用于科学研究。 社区永久,将补充自然史研究,并将告知未来的临床试验。最后 检查神经回路的新方法和多层次的综合数据分析方法 将有可能为评估、安全给药和 加速多基因剂量依赖性IDDs的临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MIRJANA MALETIC-SAVATIC其他文献

MIRJANA MALETIC-SAVATIC的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MIRJANA MALETIC-SAVATIC', 18)}}的其他基金

Effects of 16p11.2 copy number variation on neuronal development and pathology
16p11.2 拷贝数变异对神经元发育和病理学的影响
  • 批准号:
    10659523
  • 财政年份:
    2023
  • 资助金额:
    $ 20.06万
  • 项目类别:
Using MR Spectroscopy to Measure Mammalian Neurogenesis in Vivo
使用磁共振波谱测量哺乳动物体内神经发生
  • 批准号:
    10434476
  • 财政年份:
    2022
  • 资助金额:
    $ 20.06万
  • 项目类别:
Using MR Spectroscopy to Measure Mammalian Neurogenesis in Vivo
使用磁共振波谱测量哺乳动物体内神经发生
  • 批准号:
    10627832
  • 财政年份:
    2022
  • 资助金额:
    $ 20.06万
  • 项目类别:
Clinical trial readiness biomarkers for gene dosage-dependent disorders
基因剂量依赖性疾病的临床试验准备生物标志物
  • 批准号:
    10221025
  • 财政年份:
    2020
  • 资助金额:
    $ 20.06万
  • 项目类别:
Clinical trial readiness biomarkers for gene dosage-dependent disorders
基因剂量依赖性疾病的临床试验准备生物标志物
  • 批准号:
    10427281
  • 财政年份:
    2020
  • 资助金额:
    $ 20.06万
  • 项目类别:
CEREBRAL LANGUAGE ORGANIZATION IN CHILDREN WITH AUTISM SPECTRUM DISORDERS
自闭症谱系障碍儿童的大脑语言组织
  • 批准号:
    7607883
  • 财政年份:
    2007
  • 资助金额:
    $ 20.06万
  • 项目类别:
Identification and tracking of neural stem cells in vivo: a metabolomic approach
体内神经干细胞的识别和追踪:代谢组学方法
  • 批准号:
    7286826
  • 财政年份:
    2006
  • 资助金额:
    $ 20.06万
  • 项目类别:
Identification and tracking of neural stem cells in vivo: a metabolomic approach
体内神经干细胞的识别和追踪:代谢组学方法
  • 批准号:
    7145549
  • 财政年份:
    2006
  • 资助金额:
    $ 20.06万
  • 项目类别:
CEREBRAL LANGUAGE ORGANIZATION IN CHILDREN WITH AUTISM SPECTRUM DISORDERS
自闭症谱系障碍儿童的大脑语言组织
  • 批准号:
    7375380
  • 财政年份:
    2005
  • 资助金额:
    $ 20.06万
  • 项目类别:
Activity-dependent control: neural progenitor cell fate
活动依赖性控制:神经祖细胞命运
  • 批准号:
    7090009
  • 财政年份:
    2002
  • 资助金额:
    $ 20.06万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 20.06万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.06万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 20.06万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.06万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 20.06万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.06万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 20.06万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 20.06万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 20.06万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.06万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了